Exicure, Inc. (XCUR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 1, 2023, regarding events occurring on November 28, 2023. Exicure, Inc., an emerging growth company, is in the process of winding down its historical biotechnology activities and exploring broader strategic alternatives.
Key Financial Metrics and Restatement Details
The filing addresses a restatement of previously issued unaudited consolidated financial statements for the quarters ended March 31, 2023, and June 30, 2023 (the "Affected Periods"). The restatement involves reclassifying expenses from Research and Development (R&D) to General and Administrative (G&A) due to the wind-down of operations.
- Q1 2023 Adjustment: Approximately $0.6 million reclassified from R&D to G&A (separation pay and legal costs).
- Q2 2023 Adjustment: Approximately $0.9 million reclassified from R&D to G&A (office lease, equipment depreciation, legal costs, and wind-down costs).
- YTD Q2 2023 Adjustment: Approximately $1.5 million total reclassified.
- Net Loss Impact: The corrections do not impact the net loss for the Affected Periods.
The filing text does not provide current revenue, cash flow, or debt figures, as this report focuses solely on the accounting restatement.
Material Changes and Internal Controls
The primary material change is the conclusion by the Audit Committee that expenses related to the wind-down of biotechnology activities were incorrectly classified as R&D under ASC 730-10. Consequently, the financial statements for the Affected Periods are no longer reliable and will be restated via Form 10-Q/A filings.
Management has identified a material weakness in the Company's internal control over financial reporting. Additionally, disclosure controls and procedures were deemed not effective. These matters were discussed with the independent registered public accounting firm, Marcum LLP.
Outlook and Management Commentary
The Company expects to file restated financial statements for the Affected Periods on two separate Form 10-Q/A filings as soon as reasonably practical. The Form 10-Q for the quarter ended September 30, 2023, will be filed promptly thereafter and will contain additional information regarding the material weakness.
Key Facts for Investor Verification
- Verify the upcoming Form 10-Q/A filings for the March 31, 2023, and June 30, 2023 periods to review the restated financial statements.
- Monitor the Form 10-Q for the quarter ended September 30, 2023, for details on the remediation of the material weakness in internal controls.
- Confirm that the reclassification of expenses does not alter the total net loss, only the expense category presentation.
- Track the progress of the Company's strategic alternatives exploration following the wind-down of biotechnology activities.